PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.
Park S, et al. Among authors: lacombe c.
Leukemia. 2008 Sep;22(9):1698-706. doi: 10.1038/leu.2008.144. Epub 2008 Jun 12.
Leukemia. 2008.
PMID: 18548104